Data Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition
|
|
- Justin Townsend
- 5 years ago
- Views:
Transcription
1 Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular Medicine University of Florida College of Medicine Gainesville, FL Data Alert #2... Subject: HOPE: New validation for the importance of tissue ACE inhibition Dear Colleague: The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensinconverting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events. 1 This important trial is the latest in a series of carefully conducted studies supporting the hypothesis that tissue ACE inhibition is a key factor in decreasing morbidity and mortality due to coronary disease. HOPE: randomized, placebo-controlled trial of patients at high risk for cardiovascular events The HOPE study was conducted in 267 centers in 19 countries in North and South America and Europe. It lasted 4.5 years with follow-ups at 6-month intervals. 2 The study enrolled patients aged 55 or older and at high risk for cardiovascular events due to a history of ischemic disease, peripheral artery disease, stroke, or diabetes and 1 risk factor. Patients with low ejection fractions or heart failure were excluded. At baseline, 56% of the patients were normotensive and 44% were hypertensive. 1
2 Two arms of the study examined the impact of (1) tissue ACE-inhibition and (2) vitamin E on cardiovascular outcomes The two arms of the HOPE study were designed to determine whether the tissue ACE inhibitor ramipril (10 mg daily) reduces the risk of major cardiovascular events in high-risk patients, and whether the use of vitamin E (400 IU daily) reduces heart disease, stroke, and cancer. Several months before the scheduled end date, the benefits of the tissue ACE inhibitor were so clearly apparent that the ramipril arm of the study was halted. HOPE results reflect a consistent and clear benefit of tissue ACE inhibition in both primary and secondary outcomes Tissue ACE inhibition resulted in a 22% reduction in relative risk for the combined outcome of cardiovascular death, nonfatal myocardial infarction, and stroke. The risk of cardiovascular death declined by 25%, nonfatal myocardial infarction by 20%, nonfatal stroke by 31% and worsening angina by 11%. The mean blood pressure decline from baseline levels of 139/79 mm Hg was only 2.5 mm Hg in systolic blood pressure and 1 mm Hg in diastolic blood pressure, indicating that blood pressure e ffects alone explain only a small fraction of the benefits of treatment. Patients assigned ramipril were 22% less likely to develop new or worsening heart failure, 16% less likely to require emergency revascularization, and 16% less likely to be hospitalized for heart failure than those treated with placebo. There was evidence that tissue ACE inhibition prevents development of diabetes and diabetic complications, including reductions of 32% in new-onset diabetes (P = 0.002), and a 16% decline in complications related to diabetes (P = 0.03). The benefits extended to a wide cross section of patients, irrespective of age, gender, or the presence or absence of hypertension. Benefits were also observed whether or not patients were also taking aspirin, β-blockers, lipid-lowering drugs or other antihypertensive agents. 2
3 More than 90% of ACE is found locally in the tissues; only 10% occurs in the circulation The growing awareness of the importance of tissue ACE inhibition began with the identification of two renin angiotensin systems (RAS), the circulatory RAS, which regulates acute blood pressure, and tissue RAS, which influences long-term changes in vascular structure and function. More than 90% of ACE is expressed locally in the tissues, primarily in the vascular wall, as well as the heart and other tissues. 3 Expression of ACE and angiotensin II increases in disease states. ACE is a key enzyme in maintaining the balance between vasodilation and vasoconstriction in the vascular wall. It mediates the release of angiotensin II, a potent vasoconstrictor and an important initiator of atherosclerosis. Of equal importance, ACE breaks down bradykinin, a potent vasodilator which also stimulates the release of the vasodilators nitric oxide and prostacyclin. Given the profound effects of tissue ACE on the vasculature and potentially on coronary artery disease and atherosclerosis in other vascular beds, tissue affinity of ACE inhibitors at the vascular wall may be critical to their therapeutic efficacy. The relative tissueand plasma-binding potency of ACE inhibitors based on radioligand inhibitor binding studies Studies show that ACE inhibitors differ in their binding affinity for plasma and tissue ACE. 4-6 Quinapril, which has the highest degree of tissue penetration, is particularly effective at inhibiting tissue ACE. Its tissue-binding affinity exceeds that of ramipril, the HOPE study agent which is also considered a tissue ACEspecific inhibitor. 7,8 Other ACE inhibitors have lower tissue-binding capacities. 3
4 HOPE study confirms the beneficial endothelial effects of tissue ACE inhibition The HOPE study confirms and extends the impressive clinical findings of TREND, 9 BANFF, 10 QUO VADIS, 11, 12 and Hornig and Drexler. 13 Together these studies have demonstrated that tissue ACE inhibition with quinapril or ramipril significantly improves endothelial function and clinical outcomes in patients with coronary artery disease or heart failure. The HOPE data provide the strongest support to date that tissue ACE inhibition is an important factor in reducing coronary morbidity and mortality. Evidence for the anti-ischemic effects of ACE inhibitors from clinical trials The HOPE study joins the ranks of such ground-breaking long-term trials as SOLVD 14,15 and SAVE 16,17 that have established the prominent role of ACE inhibitors in the treatment and prevention of cardiovascular disease. The benefits of ACE inhibition extend over a spectrum of high-risk patients, not only with symptomatic heart failure, 18 but also with asymptomatic left ventricular dysfunction, 14,15 or at risk for developing heart failure following a myocardial infarction. 16,17 Now in one of the most compelling sets of data ever recorded, the HOPE study has confirmed the benefits of tissue ACE inhibition in high-risk patients with normal left ventricular function whether or not they have hypertension. Sincerely, Carl J. Pepine, MD 4
5 REFERENCES 1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensinconverting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med The HOPE study investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol. 1996;12: Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153: Fabris B, Chen B, Pupic V, Perich R, Johnston CI. Inhibition of angiotensin-converting enzyme (ACE) in plasma. J Cardiovasc Pharmacol. 1990; (15(suppl 2):S Fabris B, Yamada H, Cubela R, Jackson B, Mendelsohn FA, Johnston CI. Characterization of cardiac angiotensin-converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats. Br J Pharmacol. 1990;100: Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensinconverting enzyme inhibitors. J Hypertens Suppl. 1989;7(5):S11-S Moursi MG, Ganten D, Lang RE, Unger T. Antihypertensive action and inhibition of tissueconverting enzyme (CE) by three pro-drug CE inhibitors, enalapril, ramipril and perindopril, in stroke-prone spontaneously hypertensive rats. J Hypertens Suppl. 1986;4(3):S495-S Bender N, Rangoonwala B, Rosenthal J, Vasmant D. Physicochemical and enzyme-binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications. Clin Physiol Biochem. 1990;8 Suppl I: Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation. 1996;94: Anderson TJ, Overhiser RW, Haber H, Charbonneau F.A comparative study of four antihypertensive agents on endothelial function in patients with coronary disease. J Am Coll Cardiol. In press. 11. Oosterga M, Voors AA, Buikema YM, et al. Functional effects of ACE-inhibitors on angiotensin I conversion in human vasculature. J Am Coll Cardiol. 1998;31(suppl A):239A. Abstract Oosterga M, Voors AA, Veeger JGM et al. Beneficial effects of quinapril on ischemia in coronary bypass surgery patients: One year clinical follow-up of the QUO VADIS study. Circulation. 1998;98(suppl); I-636. Abstract Hornig B, Arakawa N, Haussmann D, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 1998;98: The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327: Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340(8829): Pfeffer MA, Braunwald E, Moyé LA, et al, on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327: Rutherford JD, Pfeffer MA, Moyé LA, et al, on behalf of the SAVE investigators. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. Circulation. 1994;90: The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316: UF-P-US Printed in USA 11/99 5
OVERVIEW OF CLINICAL TRIALS
Vascular Bi o l o g y in Clinical Pr a c t i c e Vol. 1, No. 2 A CME Monograph Series OVERVIEW OF CLINICAL TRIALS TO IMPROVE ENDOTHELIAL FUNCTION GUEST EDITOR Arshed A. Quyyumi, MD, MRCP National Institutes
More informationReview Article and Clinical Experience: DIABETES MELLITUS AND ENDOTHELIAL DYSFUNCTION: A CLINICAL APPROACH (Molecular Basis for Clinical Application)
Review Article and Clinical Experience: DIABETES MELLITUS AND ENDOTHELIAL DYSFUNCTION: A CLINICAL APPROACH (Molecular Basis for Clinical Application) Askandar Tjokroprawiro ABSTRACT SYNDROME-36 (presented
More informationThe Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction
The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More information1048 JACC Vol. 27, No. 5 April 1996:
1048 JACC Vol. 27, No. 5 SPECIAL ARTICLE Ongoing Clinical Trials of Angiotensin-Converting Enzyme Inhibitors for Treatment of Coronary Artery Disease in Patients With Preserved Left Ventricular Function
More informationVIEWPOINT. Journal of the American College of Cardiology Vol. 37, No. 5, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 5, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01161-5 VIEWPOINT
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationShould All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?
Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Measure Set: Acute Myocardial Infarction (AMI) Set Measure ID#: Performance Measure Name:
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationThe Angiotensin-converting Enzyme Inhibition Post Revascularization
Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00634-8 CLINICAL
More informationANGIOTENSIN-CONVERTING
BRIEF REPORT Impact of on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure Catherine Demers, MD, MSc John J. V. McMurray, MD Karl Swedberg, MD, PhD Marc A. Pfeffer,
More informationThere is growing evidence that activation of the renin
Role of Angiotensin-Converting Enzyme Inhibitors in the Coronary Artery Bypass Patient Harold L. Lazar, MD Department of Cardiothoracic Surgery, Boston University School of Medicine and Boston Medical
More information...SELECTED ABSTRACTS...
The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.
More informationSelecting an ACE inhibitor:
Selecting an ACE inhibitor: A Question of Class Effect? All members of a drug class are not therapeutically equivalent. In recent years, the concept of class effect has been under considerable debate,
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationMayo Clin Proc, March 2003, Vol 78 Role of ARBs in Treatment of Heart Failure 335 system, tissue-based RAS has long-term effects that can modify cardi
334 Concise Review for Clinicians Therapeutic Role of Angiotensin II Receptor Blockers in the Treatment of Heart Failure Concise Review for Clinicians PRERANA MANOHAR, MD, AND ILEANA L. PIÑA, MD Angiotensin
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationMetabolic Consequences of Anti Hypertensives: Is It Clinically Important?
Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?,FACA,FICA,MASH,FVBWG,MISCP CONSULTANT OF CARDIOLOGY DIRECTOR OF PORT-FOUAD HOSPITAL CCU Consideration of antihypertensive agents
More informationEffects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease
European Heart Journal (2003) 24, 475 484 Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease PROGRESS Collaborative Group 1*
More informationHypertension Management Focus on new RAAS blocker. Disclosure
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationPOSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002)
POSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002) Well designed, large scale, randomized double-blind, placebo-controlled trials have validated the efficacy of the ACE-inhibitor enalapril in
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationCardiovascular Surgery. Effects of Angiotensin-Converting Enzyme Inhibition in Low-Risk Patients Early After Coronary Artery Bypass Surgery
Cardiovascular Surgery Effects of Angiotensin-Converting Enzyme Inhibition in Low-Risk Patients Early After Coronary Artery Bypass Surgery Jean L. Rouleau, MD; Wayne J. Warnica, MD; Richard Baillot, MD;
More informationACE inhibitors as cardioprotective agents James B. Young, MD From the Kaufman Center for Heart Failure, The Cleveland Clinic Foundation, Ohio
Cardiovascular Risk Protection ACE inhibitors as cardioprotective agents James B. Young, MD From the Kaufman Center for Heart Failure, The Cleveland Clinic Foundation, Ohio James B. Young, MD The beneficial
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationClinical cases with Coversyl 10 mg
Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive
More informationORIGINAL INVESTIGATION. Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure
Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure Results From the ATLAS Trial ORIGINAL INVESTIGATION Barry M. Massie, MD; Paul W. Armstrong, MD;
More informationBLOOD PRESSURE-LOWERING TREATMENT
BLOOD PRESSURE-LOWERING TRIALS NUMBER OF PARTICIPANTS NUMBER OF PERCENTAGE OF MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 69,473 28,008 40.3% 70.2 3.2 3/5 (60%) APPENDIX 2 1 BLOOD PRESSURE-LOWERING
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More informationGoing to high altitude with heart disease. Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern
Going to high altitude with heart disease Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern stefano.rimoldi@insel.ch There are very few studies on patients with heart disease going
More informationCost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study
Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study Andre Lamy, MD, MHSc; Salim Yusuf, DPhil; Janice Pogue, MSc; Amiram Gafni,
More informationEffect of statins and ACE inhibitors alone and in combination on clinical outcome in. in patients with coronary heart disease
(2004) 18, 781 788 & 2004 Nature Publishing Group All rights reserved 0950-9240/04 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Effect of statins and ACE inhibitors alone and in combination on clinical outcome
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationRACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION
RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION DANIEL L. DRIES, M.D., M.P.H., DEREK V. EXNER, M.D., BERNARD J. GERSH,
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationStable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology
Stable Ischemic Heart Disease Ivan Anderson, MD RIHVH Cardiology Outline Review of the vascular biology of atherosclerosis Why not just cath everyone with angina? Medical management of ischemic cardiomyopathy
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationPRESCRIBING SUPPORT TEAM AUDIT: ACE Inhibitors in the treatment of stable angina (October 2007) PRESCRIBING SUPPORT TECHNICIAN:
PRESCRIBING SUPPORT TEAM AUDIT: ACE Inhibitors in the treatment of stable angina (October 2007) DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY SIGN Guideline No. 96 Management
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial John J V McMurray, Jan
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationCardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
More informationJoo-Yong Hahn, MD/PhD
Sungkyunkwan University School of Medicine Joo-Yong Hahn, MD/PhD Heart Vascular Stork Institute, Samsung Medical Center Sungkyunkwan University School of Medicine Grant support Korean Society of Interventional
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationJournal of the American College of Cardiology Vol. 33, No. 4, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(98)00675-5 Beta-Adrenergic
More informationSince the initial description of angiotensin II mediated
CLINICAL CARDIOLOGY: PHYSICIAN UPDATE Manipulation of the Renin-Angiotensin System Michael M. Givertz, MD Since the initial description of angiotensin II mediated hypertension 40 years ago, basic and clinical
More informationJournal of the American College of Cardiology Vol. 37, No. 1, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 1, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01044-5 REVIEW
More informationTreating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks
Treating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks 12th Annual Leadership Summit on Health Disparities & Congressional Black Caucus Spring Health
More informationDiabetes mellitus is a common comorbidity in patients
Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Emmanuelle Vermes, MD; Anique Ducharme, MD, MSc; Martial
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationManagement of Stage B Heart Failure
KSC 2017 Management of Stage B Heart Failure Byung Su Yoo, MD., PhD. Division of Cardiology, Wonju College of Medicine, Yonsei University, South Korea Focused on Symptom ASLVSD, ASLVDD LVH HF progression
More informationMetoprolol CR/XL in Female Patients With Heart Failure
Metoprolol CR/XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) Jalal K. Ghali, MD; Ileana L.
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationRandomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
More informationNEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD
NEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD Author affiliations: Cardiovascular Medicine Division, Pisa University Medical School, Pisa, Italy Address for correspondence:
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationPROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
Press Release Issued on behalf of Servier Date: June 6, 2012 PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE The new ESC guidelines for the diagnosis and
More informationVascular Biology in Clinical Practice
Vascular Biology in Clinical Practice Vol. 2, No. 3 A CME Monograph Series DIABETES AND CARDIOVASCULAR DISEASE: The emerging role of the endothelium and implications for treatment Highlights of a Vascular
More informationDrug Class Review on Angiotensin Converting Enzyme Inhibitors
Drug Class Review on Angiotensin Converting Enzyme Inhibitors UPDATED FINAL REPORT #1 April 2004 Roger Chou, MD Mark Helfand, MD, MPH Susan Carson, MPH Oregon Evidence-based Practice Center Oregon Health
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More information11/4/2017. but cocaine toxicity is complex: Pro thrombotic effects Progressive atherosclerosis Ventricular remodeling
2 Learning Objectives ATRIUM Fall Patient Safety Webinar Cardiology Mythbusters: Vol 1 Brent N. Reed, PharmD, BCPS AQ Cardiology Associate Professor, University of Maryland School of Pharmacy This presentation
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationHYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP
HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP What is normal blood pressure? Prehypertension 130-139/80-90 Compared with normal BP Double the risk for developing hypertension. Lifestyle
More informationRisk factors, endothelial function, and clinical outcome after coronary bypass surgery Voors, Adriaan
University of Groningen Risk factors, endothelial function, and clinical outcome after coronary bypass surgery Voors, Adriaan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationBIOAUTOMATION, 2009, 13 (4), 89-96
Preliminary Results оf Assessment of Systolic and Diastolic Function in Patients with Cardiac Syndrome X Using SPECT CT Tsonev Sv. 1, Donova T. 1, Garcheva M. 1, Matveev M. 2 1 Medical University Sofia
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationLLL Session - Nutrition support in diabetes and dyslipidemia. Dyslipidemia: targeting the management of cardiovascular risk factors. M.
ESPEN Congress Leipzig 2013 LLL Session - Nutrition support in diabetes and dyslipidemia Dyslipidemia: targeting the management of cardiovascular risk factors M. Leon Sanz (ES) Dyslipidemia: Targeting
More informationAngina and left ventricular dysfunction
European Heart Journal (1996) 17 {Supplement G), 2-7 Angina and left ventricular dysfunction H. J. Dargie From the CRI in Heart Failure, University of Glasgow, Glasgow, U. K. Angina with left ventricular
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationHospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension
(2003) 17, 665 670 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Hospital and 1-year outcome after acute myocardial infarction in patients with
More informationHeart Failure with Preserved Ejection Fraction (HFpEF): Natural History and Contemporary Management
Heart Failure with Preserved Ejection Fraction (HFpEF): Natural History and Contemporary Management Jason L. Guichard, MD, PhD Greenville Health System Department of Medicine, Carolina Cardiology Consultants
More informationThe Case for Intravenous EDTA Chelation Therapy, August, 2006 update.
The Case for Intravenous EDTA Chelation Therapy, August, 2006 update. Positive Dr. Johanna Mendez (Columbia, S.A.) and Dr. Martin Dayton discussing contents of a chelation treatment in a clinical setting
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationExperimental and epidemiological data suggest that activation
Clinical Investigation and Reports Effects of Ramipril and Vitamin E on Atherosclerosis The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) Eva M.
More informationChanges in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease
...SYMPOSIUM PROCEEDINGS... Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease Based on a presentation by Joseph L. Izzo, Jr., MD Presentation Summary Changes in systolic
More information9/17/2015. Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14.
0 1 2 Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14. 3 Slide notes: Large trials such as ALLHAT, LIFE and ASCOT show that the majority of patients with hypertension will require multiple
More informationWomen s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women
Women s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women C. Noel Bairey Merz MD Medical Director and Barbra Streisand Women s Heart Center Preventive
More informationTissue Angiotensin-Converting Enzyme Inhibitors: Are They More Effective than Serum Angiotensin-Converting Enzyme Inhibitors?
Clin. Cardiol. 28, 551 555 (2005) Tissue Angiotensin-Converting Enzyme Inhibitors: Are They More Effective than Serum Angiotensin-Converting Enzyme Inhibitors? APURVA D. SHAH, M.D., AND ROHIT R. ARORA,
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More information